Endogenous thrombopoietin levels during the clinical management of acute myeloid leukaemia

Platelets

Volumn 16, Issue 1, 2005, Pages 31-37

  Gonen, Can ^a,b   Haznedaroglu, Ibrahim C ^a   Aksu, Salih ^a   Koca, Ebru ^a   Göker, Hakan ^a   Büyükaşik, Yahya ^a   Sayinalp, Nilgün ^a   Özcebe, Osman ^a   Dündar, Semra ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b Ilica Mahallesi   (Turkey)

Author keywords

Acute myeloid leukaemia; Endogenous; Megakaryopoiesis; Thrombopoietin

Indexed keywords

ANTINEOPLASTIC AGENT; ARABINOSIDE; IDARUBICIN; THROMBOPOIETIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; APLASIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; DISEASE COURSE; DRUG MEGADOSE; FEMALE; HUMAN; MALE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE; THROMBOCYTOPENIA;

ACUTE DISEASE; ADULT; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; CASE-CONTROL STUDIES; DISEASE MANAGEMENT; FEMALE; HUMANS; INFECTION; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PLATELET COUNT; REMISSION INDUCTION; THROMBOCYTOPENIA; THROMBOPOIESIS; THROMBOPOIETIN;

EID: 12244251461     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/09537100412331272578     Document Type: Article

References (25)

1. Tornebohm E, Lockner D, Paul C. A retrospective analysis of bleeding complications in 438 patients with acute leukemia during the years 1972-1991. Eur J Haematol 1993;50:160-7.
2. Schiffer CA. Diagnosis and management of refractoriness to platelet transfusion. Blood Rev 2001;15:175-80.
3. Kaushansky K. Thrombopoietin. New Engl J Med 1998;339:746-54.
4. Haznedaroǧlu İ C, Göker H, Turgut M, Büyükaşik Y, Benekli M. Thrombopoietin as a drug: biologic expectations, clinical realities, and future directions. Clin Appl Thromb Hemost 2002;8:193-212.
5. Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995;85:2720-30.
6. Linker C. Thrombopoietin in the treatment of acute myeloid leukemia and in stem-cell transplantation. Semin Hematol 2000;37(Suppl. 4):35-40.
7. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, Patel S, Reddy SP, Hoots WK, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997;126:673-81.
8. Fanucchi M, Glaspy J, Crawford J, Garst J, Figlin R, Sheridan W, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. New Engl J Med 1997;336:404-9.
9. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, Broxmeyer HE, Kudelka AP, Freedman RS et al. Recombinant human thrombopoietin attenuates carboplatin induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000;132:364-8.
10. Archimbaud E, Ottmann OG, Yin JA, Lechner K, Dombret H, Sanz MA et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 1999;94:3694-701.
11. Schiffer CA, Miller K, Larson RA, Amrein PC, Antin JH, Zani VJ, et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 2000;95:2530-5.
12. Geissler K, Yin JA, Ganser A, Sanz MA, Szer J, Raghavachar A, et al. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukaemia - a randomized, placebo-controlled, double-blind safety and efficacy study. Ann Hematol 2003;82:677-83.
13. Koşar A, Haznedaroǧlu İC, Büyükaşik Y, Özcebe O, Kirazli S, Dündar S. Circulating thrombopoietin and interleukin-6 in newly diagnosed autoimmune versus aplastic thrombocytopenia. Haematologica 1998;83:1055-6.
14. Ertenli İ, Kiraz S, Ertürk H, Haznedaroǧlu İ C, Çelik İ, Çalgüneri M, Kirazli S. Circulating thrombopoietin in systemic sclerosis. J Rheumatol 1999;26:1939-41.
15. Haznedaroǧlu İ C, Atalar E, Öztürk MA, Özer N, Övunc K, Aksöyek S, Kes S, Kirazli S, Özmen F. Thrombopoietin inside the pulmonary vessels in patients with and without pulmonary hypertension. Platelets 2002;13:395-9.
16. Shinjo K, Takeshita A, Nakamura S, Naitoh K, Yanagi M, Tobita T, et al. Serum thrombopoietin levels in patients correlate inversely with platelet counts during chemotherapy-induced thrombocytopenia. Leukemia 1998;12:295-300.
17. Hsu HC, Lee YM, Tsai WH, Jiang ML, Ho CH, Ho CK, et al. Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome. Oncology 2002;63:64-9.
18. Espanol I, Hernandez A, Muniz-Diaz E, Ayats R, Pujol-Moix N. Usefulness of thrombopoietin in the diagnosis of peripheral thrombocytopenias. Haematologica 1999;84:608-13.
19. Wetzler M, Baer MR, Bernstein SH, Blumenson L, Stewart C, Barcos M, et al. Expression of c-mpl mRNA, the receptor for thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor response to intensive chemotherapy. J Clin Oncol 1997;15:2262-8.
20. Bouscary D, Preudhomme C, Ribrag V, Melle J, Viguie F, Picard F, et al. Prognostic value of c-mpl expression in myelodysplastic syndromes. Leukemia 1995;9:783-8.
21. Bouscary D, Prudhomme C, Quesnel B, Melle J, Picard F, Dreyfus F. c-mpl expression in hematologic disorders. Leuk Lymphoma 1995;17:19-26.
22. Takeshita A, Shinjo K, Izumi M, Ling P, Nakamura S, Naito K, et al. Quantitative expression of thrombopoietin receptor on leukaemia cells from patients with acute myeloid leukaemia and acute lymphoblastic leukaemia. Br J Haematol 1998;100:283-90.
23. Engel C, Loeffler M, Franke H, Schmitz S. Endogenous thrombopoietin serum levels during multicycle chemotherapy. Br J Haematol 1999;105:832-8.
24. Bruserud O, Foss B. Serum thrombopoietin levels in acute leukemia patients with chemotherapy-induced cytopenia - inverse correlation between serum levels and platelet counts. Leukemia 1998;12:1653-4.
25. Skomorovski K, Harpak H, Ianovski A, Vardi M, Visser TP, Hartong SC, et al. New TPO treatment schedules of increased safety and efficacy: pre-clinical validation of a thrombopoiesis simulation model. Br J Haematol. 2003;123:683-91.